BIOQUAL Inc. reports recurring financial results and governance updates as an OTC Pink/Pink Limited public company. Its announcements center on quarterly and annual revenue, income or loss before taxes, net income or loss, earnings per common share, and weighted average shares outstanding.
Company news also documents board and senior leadership changes, including retirements and appointments connected to corporate oversight and BIOQUAL's contract research program.
BIOQUAL (BIOQ) announced changes to its Board of Directors. Charles Francisco, who served as a director since 1992, retired effective December 31, 2024, at age 85. His retirement was not related to any disagreements with Board policies or practices.
Amy Johnston joined the Board on December 31, 2024, maintaining the same number of directors. Johnston brings over 30 years of healthcare and biotech industry experience. Her notable achievements include leading commercial biotech teams, supporting a Hepatitis C compound launch that achieved $1B in first-year sales, and successfully increasing a utility company's revenue from $10 million to $25 million during the pandemic. She holds dual Bachelor's degrees in Government and English and a Master's in Secondary English Education from the College of William and Mary.
BIOQUAL, Inc. (OTC Pink: BIOQ) has released its unaudited financial results for the first quarter of fiscal year 2025, ending August 31, 2024. The company reported a significant decline in performance compared to the same period last year:
- Revenue decreased to $11,770,482 from $15,578,922 in Q1 FY2024
- Income before income tax shifted to a loss of $931,825 from a profit of $1,241,183
- Net income turned to a loss of $675,325 from a profit of $899,483
- Basic and diluted earnings per share of common stock dropped to ($0.76) from $1.01
The weighted average number of shares outstanding remained stable at 894,416 for basic earnings per share and 894,405 for diluted earnings per share.
BIOQUAL (BIOQ) has announced its twenty-third dividend declaration. The company's Board of Directors has declared a dividend of $0.50 per share for shareholders of record on October 7, 2024. The dividend is payable on October 28, 2024.
This announcement demonstrates BIOQUAL's commitment to returning value to its shareholders. The dividend declaration suggests the company's financial stability and confidence in its future performance. However, it's important to note that past performance does not guarantee future results, and investors should consider their individual financial situations before making investment decisions.
BIOQUAL, Inc. (OTC Pink: BIOQ) has released its financial results for Fiscal Year 2024. The company reported:
- Revenue of $58,590,949, down from $62,663,804 in 2023
- Income Before Income Tax of $476,447, compared to $1,133,242 in 2023
- Net Income of $483,481, a decrease from $835,548 in 2023
- Basic and Diluted Earnings per Share of Common Stock both at $0.54, down from $0.93 in 2023
The Weighted Average Number of Shares Outstanding for both Basic and Diluted Earnings Per Share remained constant at 894,416.
BIOQUAL, Inc. (OTC: BIOQ) has announced a 10% reduction in workforce effective September 9, 2024, as a cost-cutting measure in response to decreased revenue and profitability over the past year. The company attributes this decline to a significant drop in demand for its services in the post-COVID-19 environment, following the development of vaccines and therapeutics.
Despite this workforce reduction, BIOQUAL does not anticipate any impact on its current services or future business prospects. The company aims to realign its cost structure to adapt to the changing market conditions while maintaining its operational capabilities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.